

Overexpression of histone deacetylase 6 contributes to accelerated migration and invasion activity of hepatocellular carcinoma cells

KIMINORI KANNO^{1,2,3}, SHOJI KANNO², HIROYUKI NITTA², NORIYUKI UESUGI⁴, TAMOSTU SUGAI⁴, TOMOYUKI MASUDA³, GO WAKABAYASHI² and CHIHAYA MAESAWA¹

¹Department of Tumor Biology, Institute of Biomedical Science, and Departments of ²Surgery and ³Pathology, School of Medicine, Iwate Medical University, Morioka; ⁴Division of Diagnostic Molecular Pathology, Department of Pathology, School of Medicine, Iwate Medical University, Morioka, Japan

Received February 25, 2012; Accepted May 18, 2012

DOI: 10.3892/or.2012.1898

Abstract. Histone deacetylase 6 (HDAC6) is a cytoplasmic enzyme that regulates many important biological processes, including cell migration, viral infection and autophagy. The aim of this study was to investigate the significance of HDAC6 in the invasion and metastasis activities of hepatocellular carcinoma (HCC). Three HCC cell lines and two primary cultures of hepatocytes were used for biological experiments. Immunohistochemistry for HDAC6 protein was also examined in 70 resected primary HCCs. Knockdown of the *HDAC6* gene in the HCC cell lines was carried out by treatment with siRNA, and their migration and invasion activities were examined by the scratch assay and Matrigel invasion assay, respectively. HDAC6 expression was greater in all of the HCC cell lines compared to the primary cultures of hepatocytes. Knockdown of *HDAC6* markedly downregulated the migration and invasion activities of all HCC cell lines ($P < 0.05$). Overexpression of HDAC6 protein to a level higher than that in the corresponding normal hepatocytes was observed in 14 (20%) of the 70 primary HCCs, and was significantly correlated with high clinical stage, number of tumors, vascular invasion and intrahepatic metastasis ($P < 0.05$). These results suggest that overexpression of the *HDAC6* protein is involved in the migration and invasion activities of HCC cells, and may be a good biomarker for prediction of intrahepatic metastasis.

Introduction

Hepatocellular carcinoma (HCC) is the fifth most common malignancy worldwide and causes nearly one million deaths a year (1). Despite the development of several modalities for

the treatment of HCC (2-7), including transcatheter arterial embolization, percutaneous ablation, surgical resection, liver transplantation and molecular targeted medicine, the prognosis of patients with HCC still remains relatively poor. One of the major factors responsible for these unsatisfactory outcomes is the high frequency of intrahepatic recurrence after curative treatment (5,8). Intrahepatic recurrence is the result of two mechanisms: intrahepatic metastasis originating from the primary cancer, and a second primary cancer arising through multicentric carcinogenesis. Intrahepatic metastasis may correlate with early recurrence and poor prognosis, whereas multicentric carcinogenesis is associated with a relatively good prognosis (9-11). With the aim of controlling intrahepatic recurrence of HCC, various studies have investigated the molecular mechanisms underlying intrahepatic metastasis (12-17), which frequently occurs at an advanced disease stage, presumably through tumor cell dispersal via the portal vein; there is a strong statistical correlation between the presence of intrahepatic metastasis and the frequency of vascular invasion (18).

Tumor invasiveness may be considered a phenomenon of cell motility. In fact, tumor cell motility plays a central role in carcinoma cell dissemination, and the cytoskeleton, a key structure of the cell machinery, is continuously remodeled during cell movement. In this context, several molecules related to the microtubule (MT)- and actin-dependent dynamics of tumor cells have been investigated as possible predictors of intrahepatic metastasis of HCCs, or targets of preventive therapy. Highly dynamic MTs are distributed randomly throughout the cell periphery, and the less dynamic ones are located between the nucleus and the leading edge of the cell (19). A previous study has revealed that overexpression of *HDAC6* increases cell motility, suggesting that deacetylation of at least one cytoplasmic HDAC protein enhances motility (20). It has also been shown that in *HDAC6*-inhibited cells, MT dynamics are decreased, leading to an increase of focal adhesion accumulation, and thus a decrease in cell motility (21). Moreover, HDAC6 protein can also interact with a different substrate, cortactin, *in vivo* and *in vitro*, and both HDAC6 catalytic domains are necessary for the interaction. Cortactin is an acetylated protein found in areas of dynamic actin assembly, such as the leading edge of migrating cells

Correspondence to: Dr Chihaya Maesawa, Department of Tumor Biology, Institute of Biomedical Science, Iwate Medical University, 2-1-1 Nishitokuta, Yahaba-cho, Morioka 028-3694, Japan
E-mail: chihaya@iwate-med.ac.jp

Key words: hepatocellular carcinoma, migration, invasion, intrahepatic metastasis, HDAC6

(22). This protein was originally identified as a substrate of *Src* tyrosine kinase, and plays a role in regulating cell motility. Disruption of HDAC6 leads to hyperacetylation of cortactin and prevents its translocation to the cell periphery, blocks association with F-actin, and impairs cell motility (23). We recently demonstrated that disruption of the *HDAC6/NACCI* (nucleus accumbens associated 1) deacetylation system markedly downregulated cell motility through MT and cortactin deacetylation (24). Thus, HDAC6 may act as a mediator between actin- and tubulin-associated proteins to regulate cell motility.

Although overexpression of *HDAC6* and its relationship with invasion and metastasis have been documented in several malignancies (24-26), it has not been documented in HCCs. The present study examined the expression of *HDAC6* in HCC cultured cells and primary tumors, and investigated its association with migration and invasion activities *in vitro* and *in vivo*.

Materials and methods

Cell culture. HCC cell lines were obtained from HSRRB (Health Science Research Resources Bank, Osaka, Japan; HLF, PLC/PRF/5) and IDAC (Institute of Department, Aging and Cancer, Tohoku University, Sendai, Japan; Hep3B). Two human normal hepatocyte cell lines, Hc-cells (Applied Cell Biology Research Institute, Human Hepatocyte Cell culture #3716, Kirkland, WA, USA) and WRL-68 (American Type Culture Collection, Rockville, MD, USA), were obtained commercially and maintained under the recommended conditions.

Surgical specimens and immunohistochemistry. Immunohistochemistry for HDAC6 protein expression was performed on tumor samples from 70 patients with HCC treated between 2006 and 2011 at the Department of Surgery, School of Medicine, Iwate Medical University, Morioka, Japan. The patient characteristics are summarized in Table I. Permission for the study was obtained from the Institutional Review Board (School of Medicine, Iwate Medical University, Morioka, Japan) and written consent was obtained from all patients before surgery.

Surgical specimens were fixed in 10% buffered formalin solution and embedded in paraffin wax, and two or more blocks were made for immunohistochemistry. Sections 4 μ m thick were cut, and stained with hematoxylin and eosin. Serial sections were stained with the avidin-biotin system on a Ventana automated immunostainer with the Ventana immunohistochemistry detection system (Ventana Medical Systems, Tucson, AZ, USA), in accordance with the manufacturer's manual. An anti-HDAC6 antibody (H-300, diluted 1:100, Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used as the primary antibody.

Western blotting. All cell lines were cultured to 70-80% confluence on 10-cm Petri dishes. Cold PBS was added, and the cells were removed from the dishes by scraping. After removal of the supernatants, the cell pellet was dissolved in cell lysis buffer [50 mM Tris-HCl, pH 8.0/150 mM NaCl/1 mM EDTA, pH 8.0/1% Triton X-100/0.1% sodium deoxycholate/0.1%

Table I. Characteristics of 70 patients with hepatocellular carcinoma.

Factor	No. of patients (%)
Gender	
Male	52 (74)
Female	18 (26)
Age (years)	
Mean (range)	64.2 (39-81)
<65	33 (47)
\geq 65	37 (53)
Clinical stage	
I	9 (13)
II	31 (45)
III	26 (38)
IVA	4 (4)
No. of tumors	
Single	50 (71)
Multiple	20 (29)
Tumor diameter (cm)	
<3	24 (35)
\geq 3	46 (65)
Lymph node status	
Yes	2 (3)
None	68 (97)
Virus infection	
HBV	28 (40)
HCV	21 (30)
HBV + HCV	1 (1)
Non infection	20 (29)
Vascular invasion	
Presence	20 (28)
Absence	50 (72)
Intrahepatic metastasis	
Presence	19 (27)
Absence	51 (73)

SDS/1 mM PMSF/10 mM NaF/2 mM Na_3VO_4 /1X protease inhibitor complete (Roche Diagnostics GmbH, Mannheim, Germany)]. Cell samples containing equal amounts of protein were mixed with 5X sample buffer, and heated for 5 min at 95°C. Protein was electrophoresed on 4-12% Nu-PAGE for 45 min at 200 V constant voltage, and then transferred onto polyvinylidene difluoride membranes (Invitrogen, Carlsbad, CA, USA) for 1 h at 30 V constant voltage. Membranes were blocked with 5% blocking reagent (Cell Signaling Technology, Danvers, MA, USA) in 1X Tris-buffered saline/Tween-20 buffer for 1 h at room temperature, and immunostained overnight with a primary antibody (HDAC6 H-300, diluted 1:250, Santa Cruz Biotechnology) at 4°C. The membranes were then rinsed with Tris-buffered saline/Tween-20 and incubated with horseradish HRP-conjugated secondary antibodies [anti-rabbit

or -mouse IgG (diluted 1:5,000, GE Healthcare, Little Chalfont, UK)] for 1 h at room temperature. Signals were detected with ECL Prime (GE Healthcare) and ChemiDoc XRS (Bio-Rad Laboratories, Hercules, CA, USA). The intensity of the detected signals was measured using 1-D analysis software (Quantity One, Bio-Rad Laboratories). For normalization of the target, glyceraldehyde-3-phosphate dehydrogenase (GAPDH, diluted 1:100; Covance, Princeton, NJ, USA) was used as an internal control.

RNA isolation and reverse transcriptase quantitative PCR. Total RNA was extracted with TRIzol reagent (Invitrogen), and transcribed to cDNA using a SuperScript III first-strand synthesis system (Invitrogen). For quantitative evaluation of relevant mRNAs, we used Custom TaqMan Gene Expression assays (HDAC6, Hs00195869_m1; Invitrogen), and an ABI PRISM 7500 instrument (Invitrogen). For normalization of the target, GAPDH (Invitrogen) was used as an internal control. All reactions (each containing 3 templates) were run in triplicate, and average fold differences were calculated by normalizing the relative expression ($\Delta\Delta C_t$ values) according to ABI User Bulletin #2.

siRNA knockdown of the HDAC6 gene. For silencing of HDAC6 gene mRNA, three pre-designed HDAC6-specific siRNA sequences (#1, s19459; #2, s19760; #3, s19461; Silencer Select siRNA, Invitrogen), and control non-specific human siRNAs (Silencer Select Pre-designed siRNA Negative Control #1, 4390843; #2, 4390844, Invitrogen) were used. siRNA transfection was performed using Lipofectamine RNAiMAX Reagent (Invitrogen) in accordance with the manufacturer's instructions.

Scratch assay. Confluent monolayer cells were scratched to create a wound, and then 0, 24 and 48 h later, three different fields of each wound were photographed with a phase-contrast microscope. Three independent experiments were performed. Measurements of the width of each wound were performed under each experimental condition. At the start of the experiment, the wound size was measured and scored as 100%. After 24 and 48 h, the width of the residual wound was measured and the average percentage of wound closure was calculated by using the free web software ImageJ (<http://rsb.info.nih.gov/ij>).

Matrigel invasion assay. The cell invasion assay was performed using a BioCoat Matrigel invasion chamber (Becton-Dickinson, Bedford, MA, USA) in accordance with the protocol provided by the manufacturer. After cells in log-phase growth had been incubated with serum-free medium for 12 h, they were detached using trypsin-EDTA. Resuspended cells were added to each chamber at a density of 5×10^4 cells in 500 μ l, and allowed to invade the Matrigel for 24 h at 37°C under a 5% CO₂ atmosphere. Cells that had not penetrated the filter were wiped out with cotton swabs, and cells that had migrated to the lower surface of the filter were stained with Quick-Diff stain kit (Symex International Reagents, Co., Ltd., Hyogo, Japan). After two washes with water, the chambers were allowed to air-dry, and the number of invading cells was counted using a light microscope. The degree of invasion was




Figure 1. Expression of HDAC6 mRNA/protein in three hepatocellular carcinoma cell lines (HLF, Hep3B and PLC) and two primary cultures of hepatocytes (Hc and WRL-68). (A) Western blotting for HDAC6 protein. Equal loading was confirmed by blotting GAPDH. Quantitative results of western blotting (B) and RT-PCR (C) for HDAC6.

expressed as the average number of migrated cells bound per microscopic field over four fields per assay, and as averages for triplicate experiments.

Statistical analysis. All data are presented as means \pm standard error. Correlations between HDAC6 protein expression and clinicopathological data were analyzed by Fisher's exact test or Kruskal-Wallis test. Mann-Whitney U test for non-parametric samples was used for analyses of biological experimental data. The level of significance was considered to be $P < 0.05$.

Results

Expression of the HDAC6 gene in cell lines and efficiency of knockdown by treatment with siRNA. We first examined HDAC6 mRNA/protein expression in three HCC cell lines and two primary-cultured normal hepatocyte lines (Fig. 1). Under the recommended culture conditions at 60-70% confluency, all of the HCC cell lines exhibited overexpression of HDAC6 mRNA/protein in comparison with normal hepatocytes (Fig. 1). We evaluated the knockdown efficiency of HDAC6-siRNAs (#1, #2 and #3; 10 nM) in one HCC cell line (PCL, Fig. 2). In comparison with negative control siRNA, all the siRNAs caused 80-90% downregulation of HDAC6 expression (Fig. 2).




Figure 2. Effects of siRNA transfection on HDAC6 protein expression in a hepatocellular carcinoma cell line (PLC). Immunoblotting (A) for HDAC6 protein and its quantification (B) at 48 h after siRNA transfection.




Figure 3. Migration activity induced by treatment with *HDAC6*-siRNA (10 nM) in hepatocellular carcinoma cell lines. (A) Photographs of scratch assays for hepatocellular carcinoma cell lines at 48 h after transfection with control or *HDAC6*-siRNA (10 nM). (B) Quantitative results at 12 and 24 h after scratching. Cell migration activity (inversely correlated with the wound area ratio) was significantly decreased in cells treated with *HDAC6*-siRNA. Average values from triplicate wells are shown. * $P < 0.05$. Ctrl., control.

Migration and invasion activities induced by treatment with HDAC6-siRNA in HCC cell lines. Using #1 *HDAC6*-siRNA, we then examined the migration activities of the three HCC cell lines by the scratch assay. *HDAC6* knockdown significantly decreased tumor cell migration activities of all three lines in comparison with the negative control at 24 and 48 h ($P < 0.05$, Mann-Whitney U-test; Fig. 3). To determine whether *HDAC6* knockdown decreased the invasiveness of HCC cells,

we performed the Matrigel invasion assay. Treatments with *HDAC6*-siRNA significantly suppressed the invasiveness of all HCC cell lines in comparison with control siRNA treatment (Fig. 4).

Immunohistochemistry of HDAC6 protein, and relationship between HDAC6 expression and clinicopathological variables in primary HCCs. We immunohistochemically examined




Figure 4. Invasion activity induced by treatment with *HDAC6*-siRNA (10 nM) in hepatocellular carcinoma cell lines. Quantitative results of the Matrigel invasion assay are shown. Cells transfected with *HDAC6* or control (Ctrl.) siRNA (10 nM) were disseminated in the 24-well Matrigel plate, and the number of cells in the bottom chamber was counted at 48 h after dissemination. A significant decrease of cell number was observed in *HDAC6*-knockdown cells as compared with the control in hepatocellular carcinoma cell lines treated with *HDAC6*-siRNA at 24 and 48 h. Average values from triplicate wells are shown.

HDAC6 protein expression in 70 patients with primary HCCs. Two independent pathologists performed the assessment of immunohistochemical staining. Immunoreactivity for *HDAC6* was diffusely positive in both tumor cells and surrounding

normal hepatocytes. Overexpression of *HDAC6* protein to a level higher than that in the corresponding normal hepatocytes was observed in 14 (20%, Fig. 5C) of the 70 primary HCCs. Lower immunoreactivity for *HDAC6* protein was found in 21 (30%, Fig. 5A) of the 70, and the remaining 35 (50%, Fig. 5B) exhibited immunoreactivity equal to that of the corresponding normal hepatocytes. Table II summarizes the relationship between *HDAC6* immunoreactivity and clinicopathological variables in all cases. Overexpression of *HDAC6* protein was significantly correlated with high clinical stage, number of tumors, vascular invasion, and intrahepatic metastasis ($P < 0.05$) (Table II).

Discussion

Several growth factors and cytokines such as transforming growth factor (27), platelet-derived growth factor (28), epidermal growth factor (29), hepatocyte growth factor (30), and extracellular matrix (31) secreted into the microenvironment surrounding tumor cells are involved in their migration and invasion. These secreted proteins and their related intracellular signaling cascades induce epithelial mesenchymal transition and accelerate the migration/invasion activity of HCC, resulting in intrahepatic metastasis. Moreover, several adhesion molecules and their related proteins such as E-cadherin, ROCK2 and CD24 also are involved (32-34). Apart from proteins secreted into the microenvironment of tumor cells and adhesion molecules, transcriptional factors such as *p300* and *Snail* (35,36) also contribute to the acquisition of metastatic potential by HCC cells. Our present study showed that overexpression of *HDAC6*, which affects both MT- and actin-dependent cell migration mechanisms, contributed to acceleration of migration/invasion activity in HCC cell lines *in vitro* and *in vivo*. In particular, the results of immunostaining of primary HCCs were well correlated with intrahepatic metastasis. *HDAC6* was thus suggested to be a newly characterized key player in the control of intrahepatic metastasis.

HDAC6 is a unique protein of the histone deacetylase family, and can affect the function of cytoplasmic non-histone proteins. It is a key regulator of many aspects of cancer biology such as the cell cycle, cell migration, drug resistance and autophagy, thereby making *HDAC6* an attractive target for cancer therapy (37). Although *HDAC6* protein is expressed in the liver as well as the heart, kidney, testis, brain, and pancreas




Figure 5. Immunohistochemistry for *HDAC6* protein in primary hepatocellular carcinomas. (A) Lower immunoreactivity for *HDAC6* protein in comparison with the corresponding normal hepatocytes (1+), (B) exhibiting immunoreactivity equal to that of the corresponding normal hepatocytes (2+), and (C) overexpression to a level higher than that in the corresponding normal hepatocytes (3+). Bars, 100 μ m.

Table II. Clinicopathological variables of patients according to HDAC6 expression.

Factor	No. of patients	Immunoreactivity of HDAC6		P-value
		0, +1, +2 (%)	+3 (%)	
Gender				
Male	52	42 (60)	10 (14)	0.513 ^a
Female	18	14 (20)	4 (6)	
Age (years)				
<65	33	27 (39)	6 (9)	0.719 ^a
≥65	37	29 (41)	8 (11)	
Clinical stage				
I, II	40	36 (51)	4 (6)	0.017 ^a
III, IV	30	20 (29)	10 (14)	
No. of tumors				
Single	50	43 (62)	7 (10)	0.047 ^a
Multiple	20	13 (18)	7 (10)	
Tumor diameter (cm)				
<3	24	20 (29)	4 (6)	0.433 ^a
≥3	46	36 (51)	10 (14)	
Virus infection				
HBV	28	22 (31)	6 (9)	0.960 ^b
HCV	21	17 (24)	4 (6)	
HBV+HCV	1	1 (1)	0 (0)	
No infection	20	6 (9)	14 (20)	
Vascular invasion				
Presence	20	12 (17)	8 (11)	0.008 ^a
Absence	50	44 (63)	6 (9)	
Intrahepatic metastasis				
Presence	19	12 (17)	7 (10)	0.031 ^a
Absence	51	44 (63)	7 (10)	

^aP-value by Fisher's exact probability test. ^bP-value by Kruskal-Wallis test. Clinical stage was defined according to the general rules for clinical and pathological study of primary liver cancer (June, 2009; Liver Cancer Study group of Japan).

(38), there has been little information about the significance of *HDAC6* in HCC tumorigenesis. It is well known that HDAC inhibitors, such as TSA and SAHA, block invasive cell motility, and therefore it is anticipated that they might be applicable for control of intrahepatic metastasis. However, most of these molecules act by altering gene expression via hyperacetylated HDAC nuclear substrates, such as histones or transcription factors, and the spectrum of targeted molecules is broad. Therefore, development of inhibitors that are more selective in targeting intrahepatic metastasis is warranted. An *HDAC6* inhibitor known as tubacin (tubulin acetylation inducer) was isolated through a multidimensional chemical genetic screen of 7,392 small molecules and a cell-based assay targeting the acetylation activity of proteins other than histones (39,40). Unlike other histone deacetylase inhibitors, tubacin was found to inhibit the deacetylation of MT in mammalian cells without affecting the level of histone acetylation, gene expression, or cell cycle progression (13,14). Furthermore, using scratch assay and trans-Matrigel migration assays, another group has demonstrated that NK84-mediated inhibition of *HDAC6* in

ovarian cancer cell lines retarded cell spreading and inhibited cell migration, respectively (41). Recently, the effectiveness of combination therapy using an *HDAC6*-selective inhibitor (ACY-1215) and bortezomib has been demonstrated in a preclinical trial (42). Thus, a new class of agents targeting *HDAC6* is currently being developed, and their efficacy is being tested.

The functions of *HDAC6* in cell migration/invasion activity may depend on deacetylation activity targeting α -tubulin and cortactin. Both proteins are also deacetylated by *SIRT2*, which belongs to another class of the histone deacetylase family. Using *SIRT2*-specific siRNA combined with tubacin treatment, Zuo *et al* (25) have demonstrated that cell migratory and invasive abilities can be dramatically suppressed. Moreover, *SIRT2*-deficient mice show gender-specific tumorigenesis, females primarily developing mammary tumors, and males developing more HCCs (43). The significance of *SIRT2* should therefore be examined in human HCC tumorigenesis, including its relationship with intrahepatic metastasis.

Acknowledgements

This study was supported in part by Grants-in-Aid for Scientific Research (22390071), the MIAST project, and a Grant-in-Aid for Strategic Medical Science Research from the Ministry of Education, Culture, Sports, Science and Technology of Japan.

References

- Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. *CA Cancer J Clin* 60: 277-300, 2010.
- Takahara T, Nitta H, Hasegawa Y, Itou N, Takahashi M and Wakabayashi G: Using sorafenib for recurrent hepatocellular carcinoma after liver transplantation - interactions between calcineurin inhibitor: two case reports. *Transplant Proc* 43: 2800-2805, 2011.
- Nitta H, Sasaki A, Fujita T, *et al*: Laparoscopy-assisted major liver resections employing a hanging technique: the original procedure. *Ann Surg* 251: 450-453, 2010.
- Sasaki A, Nitta H, Otsuka K, Takahara T, Nishizuka S and Wakabayashi G: Ten-year experience of totally laparoscopic liver resection in a single institution. *Br J Surg* 96: 274-279, 2009.
- Llovet JM, Burroughs A and Bruix J: Hepatocellular carcinoma. *Lancet* 362: 1907-1917, 2003.
- Salhab M and Canelo R: An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis. *J Cancer Res Ther* 7: 463-475, 2011.
- Thomas MB, Jaffe D, Choti MM, *et al*: Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. *J Clin Oncol* 28: 3994-4005, 2010.
- Izumi N, Asahina Y, Noguchi O, *et al*: Risk factors for distant recurrence of hepatocellular carcinoma in the liver after complete coagulation by microwave or radiofrequency ablation. *Cancer* 91: 949-956, 2001.
- Poon RT, Fan ST, Ng IO, Lo CM, Liu CL and Wong J: Different risk factors and prognosis for early and late intrahepatic recurrence after resection of hepatocellular carcinoma. *Cancer* 89: 500-507, 2000.
- Arii S, Monden K, Niwano M, *et al*: Results of surgical treatment for recurrent hepatocellular carcinoma; comparison of outcome among patients with multicentric carcinogenesis, intrahepatic metastasis, and extrahepatic recurrence. *J Hepatobiliary Pancreat Surg* 5: 86-92, 1998.
- Miyata R, Tanimoto A, Wakabayashi G, *et al*: Accuracy of preoperative prediction of microinvasion of portal vein in hepatocellular carcinoma using superparamagnetic iron oxide-enhanced magnetic resonance imaging and computed tomography during hepatic angiography. *J Gastroenterol* 41: 987-995, 2006.
- Ma WL, Hsu CL, Yeh CC, *et al*: Hepatic androgen receptor suppresses hepatocellular carcinoma metastasis through modulation of cell migration and anoikis. *Hepatology*: Feb 9, 2012 (Epub ahead of print).
- Yamazaki K, Masugi Y and Sakamoto M: Molecular pathogenesis of hepatocellular carcinoma: altering transforming growth factor-beta signaling in hepatocarcinogenesis. *Dig Dis* 29: 284-288, 2011.
- Zheng F, Liao YJ, Cai MY, *et al*: The putative tumour suppressor microRNA-124 modulates hepatocellular carcinoma cell aggressiveness by repressing ROCK2 and EZH2. *Gut* 61: 278-289, 2012.
- Fu J, Chen Y, Cao J, *et al*: p28(GANK) overexpression accelerates hepatocellular carcinoma invasiveness and metastasis via phosphoinositol 3-kinase/AKT/hypoxia-inducible factor-1alpha pathways. *Hepatology* 53: 181-192, 2012.
- Yao J, Liang L, Huang S, *et al*: MicroRNA-30d promotes tumor invasion and metastasis by targeting Galphai2 in hepatocellular carcinoma. *Hepatology* 51: 846-856, 2010.
- Mazzocca A, Liotta F and Carloni V: Tetraspanin CD81-regulated cell motility plays a critical role in intrahepatic metastasis of hepatocellular carcinoma. *Gastroenterology* 135: 244-256, 2008.
- Sakon M, Nagano H, Nakamori S, *et al*: Intrahepatic recurrences of hepatocellular carcinoma after hepatectomy: analysis based on tumor hemodynamics. *Arch Surg* 137: 94-99, 2002.
- Gundersen GG and Bulinski JC: Selective stabilization of microtubules oriented toward the direction of cell migration. *Proc Natl Acad Sci USA* 85: 5946-5950, 1988.
- Hubbert C, Guardiola A, Shao R, *et al*: HDAC6 is a microtubule-associated deacetylase. *Nature* 417: 455-458, 2002.
- Tran AD, Marmo TP, Salam AA, *et al*: HDAC6 deacetylation of tubulin modulates dynamics of cellular adhesions. *J Cell Sci* 120: 1469-1479, 2007.
- Wu H and Parsons JT: Cortactin, an 80/85-kilodalton pp60src substrate, is a filamentous actin-binding protein enriched in the cell cortex. *J Cell Biol* 120: 1417-1426, 1993.
- Luxton GW and Gundersen GG: HDAC6-pack: cortactin acetylation joins the brew. *Dev Cell* 13: 161-162, 2007.
- Tsunoda K, Oikawa H, Tada H, *et al*: Nucleus accumbens-associated 1 contributes to cortactin deacetylation and augments the migration of melanoma cells. *J Invest Dermatol* 131: 1710-1719, 2011.
- Zuo Q, Wu W, Li X, Zhao L and Chen W: HDAC6 and SIRT2 promote bladder cancer cell migration and invasion by targeting cortactin. *Oncol Rep* 27: 819-824, 2012.
- Park SY, Jun JA, Jeong KJ, *et al*: Histone deacetylases 1, 6 and 8 are critical for invasion in breast cancer. *Oncol Rep* 25: 1677-1681, 2011.
- Joshi A and Cao D: TGF-beta signaling, tumor microenvironment and tumor progression: the butterfly effect. *Front Biosci* 15: 180-194, 2010.
- Yu J, Ustach C and Kim HR: Platelet-derived growth factor signaling and human cancer. *J Biochem Mol Biol* 36: 49-59, 2003.
- Lu X and Kang Y: Epidermal growth factor signalling and bone metastasis. *Br J Cancer* 102: 457-461, 2010.
- Zhou HY, Pon YL and Wong AS: HGF/MET signaling in ovarian cancer. *Curr Mol Med* 8: 469-480, 2008.
- Yang JD, Nakamura I and Roberts LR: The tumor microenvironment in hepatocellular carcinoma: current status and therapeutic targets. *Semin Cancer Biol* 21: 35-43, 2011.
- Yang XR, Xu Y, Yu B, *et al*: CD24 is a novel predictor for poor prognosis of hepatocellular carcinoma after surgery. *Clin Cancer Res* 15: 5518-5527, 2009.
- Inayoshi J, Ichida T, Sugitani S, *et al*: Gross appearance of hepatocellular carcinoma reflects E-cadherin expression and risk of early recurrence after surgical treatment. *J Gastroenterol Hepatol* 18: 673-677, 2003.
- Wong CC, Wong CM, Tung EK, Man K and Ng IO: Rho-kinase 2 is frequently overexpressed in hepatocellular carcinoma and involved in tumor invasion. *Hepatology* 49: 1583-1594, 2009.
- Yokomizo C, Yamaguchi K, Itoh Y, *et al*: High expression of p300 in HCC predicts shortened overall survival in association with enhanced epithelial mesenchymal transition of HCC cells. *Cancer Lett* 310: 140-147, 2011.
- Miyoshi A, Kitajima Y, Kido S, *et al*: Snail accelerates cancer invasion by upregulating MMP expression and is associated with poor prognosis of hepatocellular carcinoma. *Br J Cancer* 92: 252-258, 2005.
- Aldana-Masangkay GI and Sakamoto KM: The role of HDAC6 in cancer. *J Biomed Biotechnol* 2011: 875824, 2011.
- Grozinger CM, Hassig CA and Schreiber SL: Three proteins define a class of human histone deacetylases related to yeast Hda1p. *Proc Natl Acad Sci USA* 96: 4868-4873, 1999.
- Haggarty SJ, Koeller KM, Wong JC, Grozinger CM and Schreiber SL: Domain-selective small-molecule inhibitor of histone deacetylase 6 (HDAC6)-mediated tubulin deacetylation. *Proc Natl Acad Sci USA* 100: 4389-4394, 2003.
- Haggarty SJ, Koeller KM, Wong JC, Butcher RA and Schreiber SL: Multidimensional chemical genetic analysis of diversity-oriented synthesis-derived deacetylase inhibitors using cell-based assays. *Chem Biol* 10: 383-396, 2003.
- Bazzaro M, Lin Z, Santillan A, *et al*: Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor. *Clin Cancer Res* 14: 7340-7347, 2008.
- Santo L, Hideshima T, Kung AL, *et al*: Preclinical activity, pharmacodynamic and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma. *Blood* 119: 2579-2589, 2012.
- Kim HS, Vassilopoulos A, Wang RH, *et al*: SIRT2 maintains genome integrity and suppresses tumorigenesis through regulating APC/C activity. *Cancer Cell* 20: 487-499, 2011.